Response to “Optimized Alectinib Dose Regimen for Treatment of Patients With ALK-Positive NSCLC Based on Robust Pharmacometric Analyses and Clinical Evidence”

Stefanie L. Groenland, Dieuwertje R. Geel, Jos H. Beijnen, Egbert F. Smit, Alwin D.R. Huitema, Neeltje Steeghs

Research output: Contribution to journalLetterpeer-review

2 Citations (Scopus)
Original languageEnglish
Pages (from-to)1164
Number of pages1
JournalClinical Pharmacology and Therapeutics
Issue number5
Publication statusPublished - Nov 2021
Externally publishedYes

Cite this